Inside Peptides
Search
Menu

Lixisenatide vs Exenatide: What the GetGoal-X Trial Shows

Two early GLP-1 receptor agonists built on the exendin-4 peptide from Gila monster venom. GetGoal-X compared once-daily lixisenatide with twice-daily exenatide directly. In the U.S. today, both are mainly available in narrowed forms.

FDA Approved FDA Approved Active Comparator RCT Available
Comparison banner for lixisenatide and exenatide, two exendin-4-based GLP-1 receptor agonists compared in the GetGoal-X trial.
Lixisenatide and exenatide are exendin-4-based GLP-1 receptor agonists; GetGoal-X compared them directly. Illustration © Inside Peptides.
Evidence-Based Short Answer

Evidence-Based Summary

In GetGoal-X, a 24-week open-label trial in 634 adults with type 2 diabetes on metformin, once-daily lixisenatide lowered HbA1c by 0.79 percentage points and twice-daily exenatide by 0.96. Lixisenatide met the trial's non-inferiority test but lowered HbA1c slightly less and produced slightly less weight loss; it caused less symptomatic hypoglycaemia (2.5% vs 7.9%) and less nausea (24.5% vs 35.1%). In cardiovascular outcomes trials, neither drug reduced major events compared with placebo (ELIXA for lixisenatide; EXSCEL for once-weekly exenatide), though both showed no increase in risk. In the U.S., standalone lixisenatide is no longer marketed (it remains in the Soliqua combination), and branded Byetta and Bydureon BCise are listed as discontinued, with a generic twice-daily exenatide still approved.

Medical disclaimer: Inside Peptides provides educational, evidence-first scientific analysis. Decisions about any medicine depend on the approved indication, medical history and individual supervision by a licensed clinician. We do not provide treatment, dosing or sourcing recommendations.
At a Glance

Quick Comparison: Lixisenatide vs Exenatide

A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.

Table 1: Verified regulatory, pharmacological, and clinical comparison between Lixisenatide and Exenatide.
Feature Lixisenatide Exenatide
Drug class GLP-1 receptor agonist; exendin-4-based peptide with a six-lysine tail GLP-1 receptor agonist; synthetic exendin-4
Target receptor GLP-1 receptor GLP-1 receptor
How it is given Once-daily injection under the skin (as Adlyxin); once-daily injection with insulin glargine (Soliqua) Twice-daily injection before meals (Byetta and generic); a once-weekly extended-release form is discontinued
U.S. regulatory status Adlyxin still approved but not marketed; Soliqua 100/33 combination approved and marketed for adults with type 2 diabetes Byetta and Bydureon BCise listed as discontinued; generic twice-daily exenatide approved (2024)
Direct comparison GetGoal-X: HbA1c −0.79 points; non-inferior GetGoal-X: HbA1c −0.96 points
Cardiovascular outcomes trial ELIXA vs placebo: HR 1.02 (no increase, no benefit) EXSCEL (once-weekly form) vs placebo: HR 0.91 (no increase, benefit not shown)
Main safety concerns Nausea and vomiting; hypersensitivity; pancreatitis; hypoglycaemia with insulin Nausea and vomiting; pancreatitis; hypoglycaemia with insulin or sulfonylureas; kidney injury from dehydration
WADA status (2026) Not named on the Prohibited List Not named on the Prohibited List
Receptor Biology

Two Exendin-4-Based GLP-1 Receptor Agonists

Exenatide is a synthetic copy of exendin-4, a peptide first isolated from Gila monster venom. Lixisenatide is built on the same peptide backbone. Both are short-acting GLP-1 receptor agonists with a marked effect on after-meal glucose.

Once-daily exendin-4 analogue

Lixisenatide

Primary Target: GLP-1 receptor

Affinity Profile: Selective GLP-1 receptor agonist

Follows the exendin-4 sequence but lacks one proline near the end and carries six added lysines, giving a 44-amino-acid peptide used once daily. In GetGoal-Mono it produced a pronounced after-meal glucose effect.

Twice-daily exendin-4

Exenatide

Primary Targets: GLP-1 receptor

Affinity Profile: Selective GLP-1 receptor agonist

A 39-amino-acid synthetic exendin-4. The immediate-release form is injected twice daily before meals; the discontinued extended-release form used microspheres for weekly injection.

Regulatory Status

U.S. Approval and Marketing Status

Checked 11 October 2026 against Drugs@FDA, the FDA National Drug Code Directory and DailyMed. An approval can remain on record after a company stops selling a product.

FDA Approved

Lixisenatide Status & Formulations

Drugs@FDA still lists Adlyxin (lixisenatide injection, BLA 208471, Sanofi; approved July 2016) with Prescription status, but the NDC Directory lists no Adlyxin product and DailyMed has no current Adlyxin label, so the standalone product is not being marketed. Soliqua 100/33 (insulin glargine plus lixisenatide) remains approved and listed for adults with type 2 diabetes.

FDA Approved

Exenatide Status & Formulations

Byetta (NDA 021773; first approved April 2005) is listed in Drugs@FDA as discontinued; remaining NDC listings carry marketing end dates in late 2026. Bydureon BCise (NDA 209210), the once-weekly form, is also listed as discontinued. A generic twice-daily exenatide injection (ANDA 206697) was approved in November 2024 and has Prescription status. The labelled indication is glycemic control in adults with type 2 diabetes.

Critical Regulatory Distinction

Discontinued marketing is not the same as a safety withdrawal. FDA has not announced a safety-related withdrawal for either drug. Availability can change, so check Drugs@FDA and the NDC Directory for current listings.

Human Clinical Trials

Glucose and Cardiovascular Evidence

ELIXA and EXSCEL used placebo, enrolled different populations and, for exenatide, tested the once-weekly form rather than the twice-daily form used in GetGoal-X.

Lixisenatide: Clinical Evidence Overview

GetGoal-Mono randomized 361 adults not taking glucose-lowering drugs: over 12 weeks HbA1c fell 0.54 to 0.66 points more than placebo, with nausea in 23% versus 4.1%. ELIXA randomized 6,068 adults with type 2 diabetes and a recent heart attack or unstable angina: the primary cardiovascular composite occurred in 13.4% with lixisenatide versus 13.2% with placebo (HR 1.02, 95% CI 0.89–1.17), showing non-inferiority but not superiority.

Exenatide: Clinical Evidence Overview

EXSCEL randomized 14,752 adults with type 2 diabetes, 73.1% with previous cardiovascular disease, to once-weekly extended-release exenatide or placebo. Over a median 3.2 years, the primary outcome occurred in 11.4% versus 12.2% (HR 0.91, 95% CI 0.83–1.00): non-inferior for safety, but superiority was not shown (P=0.06).

Active-Comparator RCT

GetGoal-X: Lixisenatide Versus Exenatide on Top of Metformin in Type 2 Diabetes

GetGoal-X is the published randomized trial comparing these two drugs directly. It tested whether once-daily lixisenatide was no worse than twice-daily exenatide for HbA1c (non-inferiority margin 0.4 points). Results are reported without dose amounts.

GetGoal-X: Phase 3 Non-Inferiority Trial (Diabetes Care, 2013)

Head-to-Head RCT

ClinicalTrials.gov: NCT00707031 · Study Design: Open-label, parallel-group, multicenter randomized trial; 24-week main period followed by an extension.

Participant Population: Adults with type 2 diabetes and HbA1c 7–10% on metformin; 318 assigned to lixisenatide and 316 to exenatide.

Assigned Interventions: Lixisenatide (maintenance dose) once daily versus exenatide (higher dose) twice daily. Trial regimens are context, not prescribing guidance.

Primary Endpoint: Change in HbA1c from baseline to week 24 (non-inferiority).

Direct Head-to-Head Findings

Table 2: Primary and key secondary outcomes from the GetGoal-X: Phase 3 Non-Inferiority Trial (Diabetes Care, 2013) trial.
Outcome Measure Lixisenatide Exenatide Statistical Significance & Findings
HbA1c change (percentage points) −0.79 (7.97% to 7.17%) −0.96 (7.96% to 7.01%) Difference 0.17 points (95% CI 0.033 to 0.297), favouring exenatide numerically; within the 0.4 non-inferiority margin.
Body weight (mean, start to week 24) 94.5 kg to 91.7 kg 96.7 kg to 92.9 kg Both lost weight; the authors report slightly less mean weight loss with lixisenatide.
Symptomatic hypoglycaemia 2.5% 7.9% Lower with lixisenatide (P<0.05).
Nausea 24.5% 35.1% Lower with lixisenatide (P<0.05).

Safety in GetGoal-X: Phase 3 Non-Inferiority Trial (Diabetes Care, 2013)

Overall adverse-event and serious adverse-event rates were similar (serious events 2.8% vs 2.2%). Discontinuation because of adverse events occurred in 33 people (10.4%) on lixisenatide and 41 (13.0%) on exenatide.

Essential Methodological Limitations

  • Open-label: participants and investigators knew which drug was assigned.
  • 24-week main period; no cardiovascular outcomes measured.
  • Compared with twice-daily exenatide, not the once-weekly form.
  • Sponsored by Sanofi, the maker of lixisenatide.
  • The registry lists 639 enrolled; the paper reports 634 randomized to the two arms.
Evidence Matrix

Curated Clinical Evidence Table

A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.

Table 3: Key studies evaluating Lixisenatide and Exenatide.
Study & Citation Population Comparison & Dosing Duration Main Endpoint Key Finding Methodological Limitations
GetGoal-X (Rosenstock et al., Diabetes Care 2013) 634 adults with type 2 diabetes on metformin Once-daily lixisenatide vs twice-daily exenatide 24 weeks Change in HbA1c −0.79 vs −0.96 points; non-inferior; less hypoglycaemia and nausea with lixisenatide. Open-label; industry-sponsored.
ELIXA (Pfeffer et al., NEJM 2015) 6,068 adults with type 2 diabetes and recent acute coronary syndrome Lixisenatide vs placebo Median 25 months Cardiovascular death, heart attack, stroke or unstable-angina hospitalization 13.4% vs 13.2%; HR 1.02 (95% CI 0.89–1.17). Shows no added cardiovascular risk, not benefit.
EXSCEL (Holman et al., NEJM 2017) 14,752 adults with type 2 diabetes Once-weekly exenatide vs placebo Median 3.2 years Cardiovascular death, heart attack or stroke 11.4% vs 12.2%; HR 0.91 (95% CI 0.83–1.00); superiority not shown. Once-weekly form, now discontinued in the U.S.
LIXIPARK (Meissner et al., NEJM 2024) 156 people with early Parkinson's disease Lixisenatide vs placebo 12 months plus 2-month washout MDS-UPDRS part III motor score −0.04 vs +3.04 points (difference 3.08; 95% CI 0.86–5.30). Phase 2; nausea in 46%; needs confirmation.
Exenatide-PD3 (Vijiaratnam et al., Lancet 2025) 194 people with Parkinson's disease Once-weekly exenatide vs placebo 96 weeks MDS-UPDRS part III off medication Worsened 5.7 vs 4.5 points; no evidence of disease modification (p=0.47). Tested the once-weekly form only.
Safety & Tolerability

Adverse Effects and Label Warnings

Nausea was the most common problem with both drugs. Unlike longer-acting GLP-1 drugs, the current Byetta and Soliqua labels do not carry the thyroid C-cell boxed warning.

Table 4: Evidence-supported safety considerations and adverse-reaction frequency for Lixisenatide and Exenatide.
Safety Consideration Lixisenatide Exenatide
Nausea in GetGoal-X 24.5% 35.1%
Symptomatic hypoglycaemia in GetGoal-X 2.5% 7.9%
Label warnings (Soliqua for lixisenatide; Byetta for exenatide) Serious allergic reactions including anaphylaxis, pancreatitis, never sharing pens, hypoglycaemia or hyperglycaemia with insulin changes Pancreatitis, never sharing pens, hypoglycaemia with insulin or secretagogues, kidney injury from dehydration
Cardiovascular safety ELIXA: no increase in cardiovascular events EXSCEL (once-weekly form): no increase in cardiovascular events
Pharmacological Commonalities

What Lixisenatide and Exenatide Have in Common

Where the two compounds overlap in biology, evidence or regulatory context.

Same peptide family

Both are based on exendin-4 and act on the GLP-1 receptor.

Neutral cardiovascular outcomes

ELIXA and EXSCEL both showed no increase in cardiovascular risk, but neither showed a benefit.

Narrowed U.S. availability

Standalone lixisenatide and branded exenatide products are no longer marketed; lixisenatide remains in Soliqua and generic exenatide remains approved.

Distinguishing Features

Key Scientific & Clinical Differences

Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.

Injection frequency

Lixisenatide was given once daily; immediate-release exenatide twice daily.

Glucose versus tolerability trade-off

In GetGoal-X, exenatide lowered HbA1c slightly more; lixisenatide caused less nausea and hypoglycaemia.

Parkinson's disease results

A Phase 2 lixisenatide trial reported slower motor worsening; a Phase 3 trial of once-weekly exenatide found no disease-modifying effect.

Inside Peptides Editorial Policy

Scientific Comparison vs Clinical Recommendations

Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.

Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.

Evidence Verification

Approved Uses vs Online Claims

A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.

Lixisenatide and exenatide slow Parkinson's disease

Unproven
Regulatory Context:

Neither drug is approved for Parkinson's disease.

Scientific Reality:

LIXIPARK (Phase 2, 156 people) reported less motor worsening with lixisenatide over 12 months. The larger Exenatide-PD3 Phase 3 trial found no evidence that once-weekly exenatide modifies the disease.

Older GLP-1 drugs protect the heart like newer ones

Not supported
Regulatory Context:

Neither lixisenatide nor exenatide has a cardiovascular risk-reduction indication.

Scientific Reality:

ELIXA and EXSCEL showed cardiovascular safety (no increase in events) but did not show fewer events than placebo.

Claim-Level Certainty

Evidence Strength Across Clinical Domains

Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.

Blood glucose in type 2 diabetes

Both have multiple randomized trials; GetGoal-X compared them directly.

Lixisenatide: Strong Evidence
Exenatide: Strong Evidence

Cardiovascular outcomes

Large trials consistently showed no added risk and no proven benefit.

Lixisenatide: Strong Evidence
Exenatide: Strong Evidence

Parkinson's disease

One positive Phase 2 trial for lixisenatide; a negative Phase 3 trial for once-weekly exenatide.

Lixisenatide: Early Human Evidence
Exenatide: Insufficient Evidence
Unresolved Questions

What Research Still Doesn’t Tell Us

Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.

Confirmation in Parkinson's disease

The LIXIPARK result needs a larger, longer trial; the exenatide Phase 3 result suggests caution about class-wide claims.

Long-term direct comparison

GetGoal-X lasted 24 weeks in its main period; there is no long-term head-to-head outcome trial.

Relevance to current practice

With standalone products withdrawn from the U.S. market, older trial results mainly inform the Soliqua combination and generic exenatide.

Related Compound Profiles

Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.

Bibliography & Sources

Scientific & Regulatory References

Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.

  1. Randomized controlled trial · Head-to-head
    Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    Rosenstock J et al. (2013) · Diabetes Care.
    Open-label, 24-week main period, 634 adults on metformin; Sanofi-sponsored (registry).
    Direct Source DOI: 10.2337/dc12-2709 PubMed: 23698396
  2. Discovery paper
    Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
    Eng J et al. (1992) · Journal of Biological Chemistry.
    Original isolation of exendin-4 from Gila monster venom.
    Direct Source PubMed: 1313797
  3. Trial registry record
    GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
    ClinicalTrials.gov (2016).
    GetGoal-X registry record; completed, 639 enrolled; sponsor Sanofi.
    Direct Source
  4. Cardiovascular outcomes trial
    Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
    Pfeffer MA et al. (2015) · New England Journal of Medicine.
    ELIXA: 6,068 adults with recent acute coronary syndrome; funded by Sanofi.
    Direct Source DOI: 10.1056/NEJMoa1509225 PubMed: 26630143
  5. Cardiovascular outcomes trial
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    Holman RR et al. (2017) · New England Journal of Medicine.
    EXSCEL: 14,752 adults; extended-release once-weekly exenatide; funded by Amylin.
    Direct Source DOI: 10.1056/NEJMoa1612917 PubMed: 28910237
  6. Randomized controlled trial · Monotherapy
    Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
    Fonseca VA et al. (2012) · Diabetes Care.
    Direct Source DOI: 10.2337/dc11-1935 PubMed: 22432104
  7. Randomized controlled trial · Phase 2
    Trial of Lixisenatide in Early Parkinson's Disease
    Meissner WG et al. (2024) · New England Journal of Medicine.
    156 participants with early Parkinson's disease; 12 months.
    Direct Source DOI: 10.1056/NEJMoa2312323 PubMed: 38598572
  8. Randomized controlled trial · Phase 3
    Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
    Vijiaratnam N et al. (2025) · Lancet.
    194 participants; 96 weeks; funded by NIHR and Cure Parkinson's.
    Direct Source DOI: 10.1016/S0140-6736(24)02808-3 PubMed: 39919773
  9. Official U.S. prescribing information
    Soliqua 100/33 (insulin glargine and lixisenatide) injection, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Checked 11 October 2026.
    Direct Source
  10. FDA approval record
    Drugs@FDA: Adlyxin, BLA 208471
    U.S. FDA (2026).
    Listed with Prescription status; no current NDC listing or DailyMed label (checked 11 October 2026).
    Direct Source
  11. FDA database
    FDA National Drug Code Directory
    U.S. FDA (2026).
    Searched for lixisenatide and exenatide, 11 October 2026.
    Direct Source
  12. Official U.S. prescribing information
    Byetta (exenatide) injection, U.S. label
    DailyMed / National Library of Medicine (2025).
    Label revised September 2025; checked 11 October 2026.
    Direct Source
  13. FDA approval record
    Drugs@FDA: Byetta, NDA 021773
    U.S. FDA (2026).
    Marketing status: Discontinued (checked 11 October 2026).
    Direct Source
  14. FDA approval record
    Drugs@FDA: Bydureon BCise, NDA 209210
    U.S. FDA (2026).
    Marketing status: Discontinued (checked 11 October 2026).
    Direct Source
  15. FDA approval record
    Drugs@FDA: Exenatide synthetic, ANDA 206697
    U.S. FDA (2026).
    Generic twice-daily exenatide approved 19 November 2024; Prescription status (checked 11 October 2026).
    Direct Source